The effectiveness of fibrinolysis results from the combination of regulated enzymatic activity
and the physical properties of the fibrin scaffold. Physiologically, clots or thrombi are …

Myocardial infarction and ischemic stroke are the most frequent causes of death or disability
worldwide. Due to their ability to dissolve blood clots, the thrombolytics are frequently used …

TAFI (thrombin-activable fibrinolysis inhibitor) is a recently described plasma zymogen that,
when exposed to the thrombin-thrombomodulin complex, is converted by proteolysis at Arg …

Objectives Lucilia sericata maggots are successfully used for treating chronic wounds. As
the healing process in these wounds is complicated by bacteria, particularly when residing …

Similarity between the apolipoprotein (a)(apo (a)) moiety of lipoprotein (a)(Lp (a)) and
plasminogen suggests a potentially important link between atherosclerosis and thrombosis …

BACKGROUND Both tissue plasminogen activator (tPA) in the circulation and urokinase
(uPA) in tissues cleave plasminogen (PLG) to plasmin to promote clot lysis. Tranexamic acid …

Tissue plasminogen activator (tPA) and urokinase plasminogen activator (uPA) differ in their
modes of action. Efficient tPA-mediated plasminogen activation requires binding to fibrin. In …

Plasminogen (Plg), the zymogen of plasmin (Plm), is a glycoprotein involved in fibrinolysis
and a wide variety of other physiological processes. Plg dysregulation has been implicated …

When Glu-plasminogen, the native circulating form of the zymogen, is bound to cell surfaces,
its activation is markedly enhanced compared with the reaction in solution. This results in …

Thrombin activatable fibrinolysis inhibitor (TAFI), when activated, forms a basic
carboxypeptidase that can inhibit fibrinolysis. Potential physiologic activators include both …